Febuxostat (FBX), a non-purine selective xanthine oxidase inhibitor, is effective for the prevention of hyperuricemia accompanied by tumor lysis syndrome (TLS) during cancer chemotherapy20. Here, XDH is linked to Tumor Lysis Syndrome.